Cargando…
Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis
OBJECTIVES: For patients with type 2 diabetes, newer antihyperglycaemic agents (AHA), including the dipeptidyl peptidase IV inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP1RA) and sodium glucose co‐transporter 2 inhibitors (SGLT2i) offer a lower risk of hypoglycaemia relative to s...
Autores principales: | Kamalinia, Sanaz, Josse, Robert G., Donio, Patrick J., Leduc, Lindsay, Shah, Baiju R., Tobe, Sheldon W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947712/ https://www.ncbi.nlm.nih.gov/pubmed/31922027 http://dx.doi.org/10.1002/edm2.100 |
Ejemplares similares
-
Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
por: Niezen, Sebastian, et al.
Publicado: (2019) -
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2020) -
Are the Newer Carbapenems of Any Value against Tuberculosis
por: Gonzalo, Ximena, et al.
Publicado: (2022) -
Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1
por: Sedman, Tuuli, et al.
Publicado: (2016) -
In the Quest of Drugs for Bad Bugs: Are Newer Fluoroquinolones Any Better?
por: Deep, Antariksh, et al.
Publicado: (2011)